Why the study?
Do ultrathin-strut biodegradable polymer drug-eluting stents reduce target lesion failure at 2 years compared to thin-strut durable polymer drug-eluting stents in STEMI patients undergoing primary PCI?
Do ultrathin-strut biodegradable polymer drug-eluting stents reduce target lesion failure at 2 years compared to thin-strut durable polymer drug-eluting stents in STEMI patients undergoing primary PCI?
Answers are grounded in this paper and cite their sources.
Ultrathin-strut biodegradable polymer stents demonstrated superiority over thin-strut durable polymer stents for target lesion failure at 2 years in STEMI patients regardless of PCI complexity.
In a post hoc subgroup analysis from the BIOSTEMI randomized trial, ultrathin-strut BP-SES were superior to thin-strut DP-EES with respect to TLF at 2 years among STEMI patients undergoing both complex and noncomplex pPCI.
No takes yet. Share an insight, caveat, or question.
Iglesias et al. (2023) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: